Selected research
Industry Growth & Trends
Global Recombinant Vaccines Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Recombinant Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Recombinant Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Recombinant Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Recombinant Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Recombinant Vaccines market include Johnson & Johnson, Novartis AG, Merck & Co., Inc, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AstraZeneca Plc., Serum Institute of India Pvt. Ltd and Sanofi S A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Recombinant Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Recombinant Vaccines market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Recombinant Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Recombinant Vaccines.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Recombinant Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Recombinant Vaccines Market by Company
Johnson & Johnson
Novartis AG
Merck & Co., Inc
Pfizer Inc.
GlaxoSmithKline Plc.
Bayer AG
AstraZeneca Plc.
Serum Institute of India Pvt. Ltd
Sanofi S A.
Protein Science Corporation
Novavax, Inc
Green Cross Corporation
Emergent BioSolutions Inc
Dynavax Technologies Corporation
Bharat Biotech
Recombinant Vaccines Segment by Type
Vector Recombinant Vaccines
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Recombinant Vaccines Segment by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
Recombinant Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Recombinant Vaccines companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Vector Recombinant Vaccines
- Subunit Recombinant Vaccines
- Attenuated Recombinant Vaccines
Applications
- Recombinant Human Vaccines
- Animal Recombinant Vaccines
Companies covered
- Johnson & Johnson
- Novartis AG
- Merck & Co., Inc
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Bayer AG
- AstraZeneca Plc.
- Serum Institute of India Pvt. Ltd
- Sanofi S A.
- Protein Science Corporation
- Novavax, Inc
- Green Cross Corporation
- Emergent BioSolutions Inc
- Dynavax Technologies Corporation
- Bharat Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Recombinant Vaccines Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Recombinant Vaccines Market Size by Region (2021-2032)
- 1.4.1 Global Recombinant Vaccines Market Size by Region (2021-2026)
- 1.4.2 Global Recombinant Vaccines Market Size by Region (2027-2032)
- 1.5 Key Regions Recombinant Vaccines Market Size (2021-2032)
- 1.5.1 North America Recombinant Vaccines Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Recombinant Vaccines Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Recombinant Vaccines Market Size Growth Rate (2021-2032)
- 1.5.4 South America Recombinant Vaccines Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Recombinant Vaccines Market Size Growth Rate (2021-2032)
2 Recombinant Vaccines Market by Type
- 2.1 Type Introduction
- 2.1.1 Vector Recombinant Vaccines
- 2.1.2 Subunit Recombinant Vaccines
- 2.1.3 Attenuated Recombinant Vaccines
- 2.2 Global Recombinant Vaccines Market Size by Type
- 2.2.1 Global Recombinant Vaccines Market Size Overview by Type (2021-2032)
- 2.2.2 Global Recombinant Vaccines Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Recombinant Vaccines Market Size Forecasted by Type (2027-2032)
- 2.3 Global Recombinant Vaccines Market Size by Regions
- 2.3.1 North America Recombinant Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Recombinant Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Recombinant Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Recombinant Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Recombinant Vaccines Market Size Breakdown by Type (2021-2026)
3 Recombinant Vaccines Market by Application
- 3.1 Type Introduction
- 3.1.1 Recombinant Human Vaccines
- 3.1.2 Animal Recombinant Vaccines
- 3.2 Global Recombinant Vaccines Market Size by Application
- 3.2.1 Global Recombinant Vaccines Market Size Overview by Application (2021-2032)
- 3.2.2 Global Recombinant Vaccines Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Recombinant Vaccines Market Size Forecasted by Application (2027-2032)
- 3.3 Global Recombinant Vaccines Market Size by Regions
- 3.3.1 North America Recombinant Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Recombinant Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Recombinant Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Recombinant Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Recombinant Vaccines Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Recombinant Vaccines Industry Trends
- 4.2 Recombinant Vaccines Industry Drivers
- 4.3 Recombinant Vaccines Industry Opportunities and Challenges
- 4.4 Recombinant Vaccines Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Recombinant Vaccines Revenue (2021-2026)
- 5.2 Global Recombinant Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Recombinant Vaccines Key Company Headquarters & Area Served
- 5.4 Global Recombinant Vaccines Company, Product Type & Application
- 5.5 Global Recombinant Vaccines Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Recombinant Vaccines Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Recombinant Vaccines Players Market Share by Revenue in 2025
- 5.6.3 2025 Recombinant Vaccines Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Johnson & Johnson Recombinant Vaccines Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 Novartis AG
- 6.2.1 Novartis AG Company Information
- 6.2.2 Novartis AG Business Overview
- 6.2.3 Novartis AG Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis AG Recombinant Vaccines Product Portfolio
- 6.2.5 Novartis AG Recent Developments
- 6.3 Merck & Co., Inc
- 6.3.1 Merck & Co., Inc Company Information
- 6.3.2 Merck & Co., Inc Business Overview
- 6.3.3 Merck & Co., Inc Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck & Co., Inc Recombinant Vaccines Product Portfolio
- 6.3.5 Merck & Co., Inc Recent Developments
- 6.4 Pfizer Inc.
- 6.4.1 Pfizer Inc. Company Information
- 6.4.2 Pfizer Inc. Business Overview
- 6.4.3 Pfizer Inc. Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Pfizer Inc. Recombinant Vaccines Product Portfolio
- 6.4.5 Pfizer Inc. Recent Developments
- 6.5 GlaxoSmithKline Plc.
- 6.5.1 GlaxoSmithKline Plc. Company Information
- 6.5.2 GlaxoSmithKline Plc. Business Overview
- 6.5.3 GlaxoSmithKline Plc. Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolio
- 6.5.5 GlaxoSmithKline Plc. Recent Developments
- 6.6 Bayer AG
- 6.6.1 Bayer AG Company Information
- 6.6.2 Bayer AG Business Overview
- 6.6.3 Bayer AG Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Bayer AG Recombinant Vaccines Product Portfolio
- 6.6.5 Bayer AG Recent Developments
- 6.7 AstraZeneca Plc.
- 6.7.1 AstraZeneca Plc. Company Information
- 6.7.2 AstraZeneca Plc. Business Overview
- 6.7.3 AstraZeneca Plc. Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 AstraZeneca Plc. Recombinant Vaccines Product Portfolio
- 6.7.5 AstraZeneca Plc. Recent Developments
- 6.8 Serum Institute of India Pvt. Ltd
- 6.8.1 Serum Institute of India Pvt. Ltd Company Information
- 6.8.2 Serum Institute of India Pvt. Ltd Business Overview
- 6.8.3 Serum Institute of India Pvt. Ltd Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Serum Institute of India Pvt. Ltd Recombinant Vaccines Product Portfolio
- 6.8.5 Serum Institute of India Pvt. Ltd Recent Developments
- 6.9 Sanofi S A.
- 6.9.1 Sanofi S A. Company Information
- 6.9.2 Sanofi S A. Business Overview
- 6.9.3 Sanofi S A. Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Sanofi S A. Recombinant Vaccines Product Portfolio
- 6.9.5 Sanofi S A. Recent Developments
- 6.10 Protein Science Corporation
- 6.10.1 Protein Science Corporation Company Information
- 6.10.2 Protein Science Corporation Business Overview
- 6.10.3 Protein Science Corporation Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Protein Science Corporation Recombinant Vaccines Product Portfolio
- 6.10.5 Protein Science Corporation Recent Developments
- 6.11 Novavax, Inc
- 6.11.1 Novavax, Inc Company Information
- 6.11.2 Novavax, Inc Business Overview
- 6.11.3 Novavax, Inc Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Novavax, Inc Recombinant Vaccines Product Portfolio
- 6.11.5 Novavax, Inc Recent Developments
- 6.12 Green Cross Corporation
- 6.12.1 Green Cross Corporation Company Information
- 6.12.2 Green Cross Corporation Business Overview
- 6.12.3 Green Cross Corporation Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Green Cross Corporation Recombinant Vaccines Product Portfolio
- 6.12.5 Green Cross Corporation Recent Developments
- 6.13 Emergent BioSolutions Inc
- 6.13.1 Emergent BioSolutions Inc Company Information
- 6.13.2 Emergent BioSolutions Inc Business Overview
- 6.13.3 Emergent BioSolutions Inc Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Emergent BioSolutions Inc Recombinant Vaccines Product Portfolio
- 6.13.5 Emergent BioSolutions Inc Recent Developments
- 6.14 Dynavax Technologies Corporation
- 6.14.1 Dynavax Technologies Corporation Company Information
- 6.14.2 Dynavax Technologies Corporation Business Overview
- 6.14.3 Dynavax Technologies Corporation Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Dynavax Technologies Corporation Recombinant Vaccines Product Portfolio
- 6.14.5 Dynavax Technologies Corporation Recent Developments
- 6.15 Bharat Biotech
- 6.15.1 Bharat Biotech Company Information
- 6.15.2 Bharat Biotech Business Overview
- 6.15.3 Bharat Biotech Recombinant Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Bharat Biotech Recombinant Vaccines Product Portfolio
- 6.15.5 Bharat Biotech Recent Developments
7 North America
- 7.1 North America Recombinant Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Recombinant Vaccines Market Size by Country (2021-2026)
- 7.3 North America Recombinant Vaccines Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Recombinant Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Recombinant Vaccines Market Size by Country (2021-2026)
- 8.3 Europe Recombinant Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Recombinant Vaccines Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Recombinant Vaccines Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Recombinant Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Recombinant Vaccines Market Size by Country (2021-2026)
- 10.3 South America Recombinant Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Recombinant Vaccines Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Recombinant Vaccines Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst